Anti-CD3 monoclonal antibodies have been shown to reduce insulin requirements for at least the first year of recent-onset disease by suppressing autoimmune T-cell response, and these drugs may delay onset of type 1 diabetes in high-risk family members of patients with type 1 diabetes.